PT  - JOURNAL ARTICLE
AU  - Javier Castillo-Olivares
AU  - David A. Wells
AU  - Matteo Ferrari
AU  - Andrew Chan
AU  - Peter Smith
AU  - Angalee Nadesalingam
AU  - Minna Paloniemi
AU  - George Carnell
AU  - Luis Ohlendorf
AU  - Diego Cantoni
AU  - Martin Mayora-Neto
AU  - Phil Palmer
AU  - Paul Tonks
AU  - Nigel Temperton
AU  - Ralf Wagner
AU  - Patrick Neckermann
AU  - David Peterhoff
AU  - Rainer Doffinger
AU  - Sarah Kempster
AU  - Ashley Otter
AU  - Amanda Semper
AU  - Tim Brooks
AU  - Mark Page
AU  - Anna Albecka
AU  - Leo C. James
AU  - John Briggs
AU  - Wilhelm Schwaeble
AU  - Helen Baxendale
AU  - Jonathan Heeney
TI  - Towards Internationally standardised humoral Immune Correlates of Protection from SARS-CoV-2 infection and COVID-19 disease
AID  - 10.1101/2021.05.21.21257572
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.21.21257572
4099  - http://medrxiv.org/content/early/2021/05/23/2021.05.21.21257572.short
4100  - http://medrxiv.org/content/early/2021/05/23/2021.05.21.21257572.full
AB  - Precision monitoring of antibody responses during the COVID-19 pandemic is increasingly important during large scale vaccine rollout and rise in prevalence of Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2) variants of concern (VOC). Equally important is defining Correlates of Protection (CoP) for SARS-CoV-2 infection and COVID-19 disease. Data from epidemiological studies and vaccine trials identified virus neutralising antibodies (Nab) and SARS-CoV-2 antigen-specific (notably RBD, and S) binding antibodies as candidate CoP. In this study, we used the World Health Organisation (WHO) international standard to benchmark neutralising antibody responses and a large panel of binding antibody assays to compare convalescent sera obtained from: a) COVID-19 patients; b) SARS-CoV-2 seropositive healthcare workers (HCW) and c) seronegative HCW. The ultimate aim of this study, was to identify biomarkers of humoral immunity that could be used as candidate CoP in internationally accepted unitage. Whenever suitable, the antibody levels of the samples studied were expressed in International Units (INU) for virus neutralisation assays or International Binding Antibody Units (BAU) for ELISA tests. In this work we used commercial and non-commercial antibody binding assays; a lateral flow test for detection of SARS-CoV-2-specific IgG / IgM; a high throughput multiplexed particle flow cytometry assay for SARS-CoV-2 Spike (S), Nucleocapsid (N) and Receptor Binding Domain (RBD) proteins); a multiplex antigen semi-automated immuno-blotting assay measuring IgM, IgA and IgG; a pseudotyped microneutralisation test (pMN) and electroporation-dependent neutralisation assay (EDNA). Our results indicate that overall, severe COVID-19 patients showed statistically significantly higher levels of SARS-CoV-2-specific neutralising antibodies (average 1029 IU/ml) than those observed in seropositive HCW with mild or asymptomatic infections (379 IU/ml) and that clinical severity scoring, based on WHO guidelines was tightly correlated with neutralisation and RBD / S binding assays. In addition, there was a positive correlation between severity, N-antibody assays and intracellular virus neutralisation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was undertaken by the Humoral Immune Correlates to COVID-19 (HICC) consortium, funded by the UKRI and NIHR; grant number G107217 (COV0170 - HICC: Humoral Immune Correlates for COVID-19). RW and SE received funding from the StMWK (ForCOVID, Bavaria, Germany)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study approved by Research Ethics Committee Wales, IRAS: 96194 12/WA/0148. Amendment 5All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available referred to in the manuscript is available on request